HPS Pharmacies wishes to advise that AstraZeneca is discontinuing Symbicort® Rapihaler™ 50/3 as follows:

Symbicort® Rapihaler™
Budesonide 50 µg + Formoterol fumarate dihydrate 3 µg
ARTG 158898

Symbicort® Rapihaler™ 50/3 is set to be discontinued by end-August 2024, although warehouse supplies are already exhausted.

This product is a low-strength option that is mainly prescribed for children, although the discontinuation may also affect some adults. Patients should be encouraged to discuss alternative therapies with their prescriber as soon as possible. This may require changing to a different delivery device. The Asthma Australia website is a useful resource for instructional videos on how to use asthma devices correctly.

Retain this notice in a prominent position, including in other related business units for at least one month. Report any problems identified with medicines, vaccines or medical devices to the TGA.

Should you require further information regarding this matter, please contact AstraZeneca on 1800 805 342 or your pharmacist at HPS Pharmacies.

Download PDF

Subscribe Knowledge Centre Updates

Enter your details to receive Knowledge Centre updates